Astral Laboratories complies with SEBI norms for FY26

2 min read     Updated on 27 May 2026, 03:41 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Astral Laboratories Limited has reported full compliance with SEBI regulations for FY26, acquiring a material subsidiary. The secretarial audit confirmed adherence to governance standards, with no non-compliances or regulatory actions noted.

powered bylight_fuzz_icon
41422263

*this image is generated using AI for illustrative purposes only.

Astral Laboratories Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The Annual Secretarial Compliance Report, submitted to BSE Limited, certifies that the listed entity adhered to the provisions of the SEBI Act, 1992, and the Securities Contracts (Regulation) Act, 1956, along with relevant circulars and guidelines.

The report, issued by M/s Mahendra Khandelwal & Co., Practicing Company Secretaries, examined the company's documents, records, and filings made to the stock exchanges. It confirmed that Astral Laboratories maintained a functional website with timely dissemination of information and accurate web-links as required under Regulation 27(2) of the LODR Regulations. The company also adopted and updated all applicable policies under SEBI Regulations with board approval.

During the review period, the company acquired a wholly owned material subsidiary, Sriven Pharmachem India Private Limited. The secretarial audit verified that disclosures regarding this and other subsidiaries were made in accordance with regulatory requirements. Additionally, the performance evaluation of the Board, Independent Directors, and Committees was conducted as prescribed.

The audit confirmed that none of the directors were disqualified under Section 164 of the Companies Act, 2013. The company also complied with regulations concerning related party transactions, obtaining prior approval from the Audit Committee where necessary. No actions were taken by SEBI or stock exchanges against the entity, its promoters, or directors during the financial year.

Compliance Status

Particulars Compliance Status Observations / Remarks by PCS
Secretarial Standards YES
Adoption and updation of Policies YES
Maintenance and disclosures on Website YES
Disqualification of Director YES
Details related to Subsidiaries YES Acquired wholly owned material subsidiary Sriven Pharmachem India Private Limited
Preservation of Documents YES
Performance Evaluation YES
Related Party Transactions YES
Disclosure of events or information
Prohibition of Insider Trading YES
Actions taken by SEBI or Stock Exchange YES
Resignation of statutory auditors NA No resignation of statutory auditors
Additional non-compliances YES No additional non-compliances observed
Employee Benefit Scheme Documents NA Company does not have any Employee Stock Option Scheme

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+5.38%+17.53%-11.19%-1.37%-9.34%+801.71%

How will the acquisition of Sriven Pharmachem India Private Limited impact Astral Laboratories' revenue and market position in the upcoming fiscal year?

What strategic initiatives is the company pursuing following the full compliance certification to enhance shareholder value?

Are there any plans to introduce an Employee Stock Option Scheme (ESOS) in the future to attract and retain talent?

Astal Laboratories subsidiary appoints new statutory auditor

1 min read     Updated on 20 May 2026, 02:43 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Astal Laboratories Limited's subsidiary, Sriven Pharmachem India Private Limited, appointed M/s. Khedar Ankur & Associates Chartered Accountants as its statutory auditor effective May 19, 2026. This fills the vacancy left by the resignation of M/s. Balaji V & Co.

powered bylight_fuzz_icon
40813946

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited has disclosed the appointment of a new statutory auditor for its material wholly owned subsidiary, M/s. Sriven Pharmachem India Private Limited. This decision was taken during the board meeting of the subsidiary held on May 19, 2026, to fill the casual vacancy caused by the resignation of M/s. Balaji V & Co.

The board approved the appointment of M/s. Khedar Ankur & Associates Chartered Accountants, bearing Firm Registration Number 040042N. The appointment is effective from May 19, 2026. The firm is a professionally managed proprietorship based in Delhi, led by CA Ankur Khedar.

Auditor Profile

M/s. Khedar Ankur & Associates provides a wide range of professional services. These include statutory audits, internal audits, tax audits, and direct and indirect taxation. The firm also offers GST advisory and compliance, accounting and financial reporting support, certification services, and other regulatory advisory assignments across diverse sectors.

Appointment Details

The following table summarizes the key details regarding the change in statutory auditors:

Particulars Details
Name of the Firm M/s. Khedar Ankur & Associates Chartered Accountants
Firm Registration Number 040042N
Reason for change Appointment of Auditor
Date of appointment May 19, 2026

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+5.38%+17.53%-11.19%-1.37%-9.34%+801.71%

What were the specific reasons behind M/s. Balaji V & Co.'s resignation, and could those circumstances signal any underlying financial or governance concerns at Sriven Pharmachem India Private Limited?

How might the transition to a smaller Delhi-based proprietorship firm impact the audit quality and regulatory scrutiny of Astal Laboratories' material subsidiary going forward?

Will the auditor change at the subsidiary level prompt Astal Laboratories to review or realign its audit arrangements at the parent company level as well?

More News on Astal Laboratories

1 Year Returns:-9.34%